World Disease Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of World Disease Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Strep Throat
Advancis' Amoxicillin achieves clinical endpoints in PULSYS phase III trial for strep throat
September 5th, 2006
Advancis Pharmaceutical Corp. (AVNC) announced that its Amoxicillin PULSYS phase III clinical trial for the treatment of adults and adolescents with pharyngitis/tonsillitis due to Group A streptococcal infections (commonly referred to as strep throat) achieved its desired microbiological and clinical endpoints. Positive trial results were achieved with a once-daily 775 milligram dose of Amoxicillin PULSYS for 10 days. The most commonly prescribed treatment for the management of Group A streptococcal pharyngitis is 500 milligrams of amoxicillin dosed three-times daily for a period of 10 days. Amoxicillin is currently not approved for once-daily dosing to treat...
Source: World Disease Weekly (2006-09-05)
|
